RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE
  3. Financials
  4. Net income margin (%)

Viridian Therapeutics, Inc.\DEVRDN

Market cap
$2.6B
P/E ratio
SummaryFinancials
Period EndNet income margin (%) YoY (%)
Dec 31, 2024-89,387.1+18.06%
Dec 31, 2023-75,711.5+933.01%
Dec 31, 2022-7,329.2+173.46%
Dec 31, 2021-2,680.2-74.58%
Dec 31, 2020-10,544.3+1023.35%
Dec 31, 2019-938.6+140.70%
Dec 31, 2018-390-41.12%
Dec 31, 2017-662.3+74.38%
Dec 31, 2016-379.8-14.91%
Dec 31, 2015-446.3+144.38%
Dec 31, 2014-182.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)